Abstract
This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference107 articles.
1. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.;A Hughes;Brain.,2002
2. Paralysis agitans. I. Pathologische Anatomie.;F Lewy;Handbuch der Neurologie
3. Alpha-synuclein in Lewy bodies.;M Spillantini;Nature.,1997
4. Contribution a l'etude l'anatomie pathologique du locus Niger de soemmering: avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson;C Tretiakoff,1919
5. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].;W Birkmayer;Wien Klin Wochenschr.,1961
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献